tranexamic acid has been researched along with Rosacea in 7 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
Rosacea: A cutaneous disorder primarily of convexities of the central part of the FACE, such as FOREHEAD; CHEEK; NOSE; and CHIN. It is characterized by FLUSHING; ERYTHEMA; EDEMA; RHINOPHYMA; papules; and ocular symptoms. It may occur at any age but typically after age 30. There are various subtypes of rosacea: erythematotelangiectatic, papulopustular, phymatous, and ocular (National Rosacea Society's Expert Committee on the Classification and Staging of Rosacea, J Am Acad Dermatol 2002; 46:584-7).
| Excerpt | Relevance | Reference |
|---|---|---|
| " Tranexamic acid (TXA) acts as a plasmin inhibitor to reduce blood loss and is also used to treat rosacea due to its anti-inflammatory effects." | 9.51 | Adjunctive treatment for acne vulgaris by tranexamic acid. ( Chaichalotornkul, S; Charoenwattanayothin, A; Saiwichai, T, 2022) |
| "We included 20 patients, having erythematotelangiectatic rosacea." | 6.90 | The new therapeutic choice of tranexamic acid solution in treatment of erythematotelangiectatic rosacea. ( Bageorgou, F; Kontochristopoulos, G; Tzanetakou, V; Vasalou, V, 2019) |
| "Tranexamic acid (TXA) is an antifibrinolytic drug that was recently used for the treatment of ETR." | 5.62 | Intradermal tranexamic acid microinjections: a novel treatment option for erythematotelangiectatic rosacea. ( Bacha, T; Belajouza Noueiri, C; Daadaa, N; Goucha, S; Jones, M; Karray, M; Litaiem, N; Zeglaoui, F, 2021) |
| " Tranexamic acid (TXA) acts as a plasmin inhibitor to reduce blood loss and is also used to treat rosacea due to its anti-inflammatory effects." | 5.51 | Adjunctive treatment for acne vulgaris by tranexamic acid. ( Chaichalotornkul, S; Charoenwattanayothin, A; Saiwichai, T, 2022) |
| "Rosacea is a chronic inflammatory cutaneous disease characterized by immune system anomalies and vascular hyperreactivity." | 5.51 | Tranexamic acid ameliorates rosacea symptoms through regulating immune response and angiogenesis. ( Deng, Z; Li, J; Li, Y; Tang, Y; Wang, B; Xie, H; Xu, S; Yuan, X; Zhang, Y; Zhao, Z; Zuo, Z, 2019) |
| "We included 20 patients, having erythematotelangiectatic rosacea." | 2.90 | The new therapeutic choice of tranexamic acid solution in treatment of erythematotelangiectatic rosacea. ( Bageorgou, F; Kontochristopoulos, G; Tzanetakou, V; Vasalou, V, 2019) |
| "Tranexamic acid (TXA) is an antifibrinolytic drug that was recently used for the treatment of ETR." | 1.62 | Intradermal tranexamic acid microinjections: a novel treatment option for erythematotelangiectatic rosacea. ( Bacha, T; Belajouza Noueiri, C; Daadaa, N; Goucha, S; Jones, M; Karray, M; Litaiem, N; Zeglaoui, F, 2021) |
| "Rosacea is a chronic inflammatory cutaneous disease characterized by immune system anomalies and vascular hyperreactivity." | 1.51 | Tranexamic acid ameliorates rosacea symptoms through regulating immune response and angiogenesis. ( Deng, Z; Li, J; Li, Y; Tang, Y; Wang, B; Xie, H; Xu, S; Yuan, X; Zhang, Y; Zhao, Z; Zuo, Z, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 3 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Charoenwattanayothin, A | 1 |
| Saiwichai, T | 1 |
| Chaichalotornkul, S | 1 |
| Jakhar, D | 1 |
| Kaur, I | 1 |
| Misri, R | 1 |
| Daadaa, N | 1 |
| Litaiem, N | 1 |
| Karray, M | 1 |
| Bacha, T | 1 |
| Jones, M | 1 |
| Belajouza Noueiri, C | 1 |
| Goucha, S | 1 |
| Zeglaoui, F | 1 |
| Bageorgou, F | 1 |
| Vasalou, V | 1 |
| Tzanetakou, V | 1 |
| Kontochristopoulos, G | 1 |
| Li, Y | 1 |
| Xie, H | 1 |
| Deng, Z | 1 |
| Wang, B | 1 |
| Tang, Y | 1 |
| Zhao, Z | 1 |
| Yuan, X | 1 |
| Zuo, Z | 1 |
| Xu, S | 1 |
| Zhang, Y | 1 |
| Li, J | 1 |
| Kwon, HJ | 1 |
| Suh, JH | 1 |
| Ko, EJ | 1 |
| Kim, BJ | 1 |
| Kim, MS | 1 |
| Chang, SE | 1 |
| Haw, S | 1 |
| Bak, H | 1 |
| Kim, YJ | 1 |
| Lee, MW | 1 |
2 trials available for tranexamic acid and Rosacea
| Article | Year |
|---|---|
Adjunctive treatment for acne vulgaris by tranexamic acid.
Topics: Acne Vulgaris; Anti-Inflammatory Agents; Double-Blind Method; Humans; Rosacea; Tranexamic Acid; Trea | 2022 |
The new therapeutic choice of tranexamic acid solution in treatment of erythematotelangiectatic rosacea.
Topics: Acupuncture Therapy; Adult; Aged; Antifibrinolytic Agents; Bandages; Combined Modality Therapy; Derm | 2019 |
5 other studies available for tranexamic acid and Rosacea
| Article | Year |
|---|---|
Topical 10% tranexamic acid for erythematotelangiectatic steroid-induced rosacea.
Topics: Humans; Rosacea; Steroids; Tranexamic Acid | 2022 |
Intradermal tranexamic acid microinjections: a novel treatment option for erythematotelangiectatic rosacea.
Topics: Antifibrinolytic Agents; Humans; Microinjections; Retrospective Studies; Rosacea; Tranexamic Acid; T | 2021 |
Tranexamic acid ameliorates rosacea symptoms through regulating immune response and angiogenesis.
Topics: Animals; Antimicrobial Cationic Peptides; Cathelicidins; Cell Line; Human Umbilical Vein Endothelial | 2019 |
Combination treatment of propranolol, minocycline, and tranexamic acid for effective control of rosacea.
Topics: Adult; Anti-Bacterial Agents; Dermatologic Agents; Drug Therapy, Combination; Female; Humans; Minocy | 2017 |
Tranexamic acid solution soaking is an excellent approach for rosacea patients: a preliminary observation in six patients.
Topics: Adult; Antifibrinolytic Agents; Asian People; Dermatitis, Irritant; Female; Humans; Middle Aged; Ros | 2013 |